| Emergent BioSolutions Inc. Q1 2010 Earnings Call Transcript Emergent BioSolutions Inc. (EBS)Q1 2010 Earnings CallMay 5, 2010 05:00 a.m. ETComplete Story » seekingalpha.com |
The Best Biotech Takeover Targets R. Scott Raynovich submits:Many biotech stocks surged on the Friday before a long weekend on speculation that they could be takeover targets. Biogen-Idec (BIIB) and Allegan (AGN) were up 5% and 6%, respectively. This, on a day when the broader market was selling off. Bloomberg first got the rumor-mill going when it reported that Sanofi-Aventis (SNY) is on the prowl for a large biotech company. The rumors make sense, as big pharma needs to consume biotech companies in order to keep their product pipelines flowing. I decided to take a look at which biotech companies would be most attractive from a valuation standpoint. The three companies mentioned cited by Bloomberg as targets include Allergan (AGN), Biogen-Idec (BIIB), and Genzyme (GENZ). I also tossed in Amgen (AMGN), Gilead (GILD), and Celgene (CELG), mentioned in a WSJ blog.Complete Story » seekingalpha.com |
Aetna Contracts CVS to Run PBM Aetna is contracting out its pharmacy-benefit business to CVS Caremark in a 12-year deal, and the health insurer posted a 42% increase in profit. online.wsj.com |
Why AEterna Zentaris Is Worth Double Jeremy Richards submits:AEterna Zentaris (AEZS) is a biotech company that is undervalued and deserves a much high stock price based on analyst opinions and healthy pipeline prospects. AEZS, which now is at $1.15 per share, doesn't reflect the positive opinion from the EMA (European Medicines Agency) for its lead anticancer proprietary compound, perifosine. I firmly believe AEZS is now a must own.AEZS has out-licensed rights for perifosine to Keryx Biopharmaceuticals (KERX) for North America. I consider AEZS to be almost 100% below fair value given the enormous amount of potential world wide revenue from perifosine.Complete Story » seekingalpha.com |
Rules-Based Medicine, Inc. Announces Commercial Release of VeriPsych™, Diagnostic Aid for Recent Onset Schizophrenia - Video Rules-Based Medicine, Inc. Announces Commercial Release of VeriPsych™, Diagnostic Aid for Recent Onset Schizophrenia feedproxy.google.com |